Loading…
Lobbying Spend
—
Filings
10
Firms Hired
1
Active Period
2012–2013
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Drug Quality and Security Act
2013 · fourth_quarter · Firm: HOLLAND & KNIGHT LLP
Lobbied regarding proposals to regulate pharmaceutical supply chain to ensure appropriate treatment of secondary wholesalers; Lobbied regarding the Drug Quality and Security Act, H.R. 3204.
Client expense: — · Firm income: —
Matched citations: H.R. 3204
Safeguarding America's Pharmaceuticals Act of 2013
2013 · third_quarter · Firm: HOLLAND & KNIGHT LLP
Lobbied regarding proposals to regulate pharmaceutical supply chain to ensure appropriate treatment of secondary wholesalers; Conference between S.959, Pharmaceutical Quality Security & Accountability Act and H.R. 1919, Safeguarding America's Pharmaceuticals Act of 2013.
Client expense: — · Firm income: $10,000
Matched citations: H.R. 1919
Pharmaceutical Quality, Security, and Accountability Act
2013 · third_quarter · Firm: HOLLAND & KNIGHT LLP
Lobbied regarding proposals to regulate pharmaceutical supply chain to ensure appropriate treatment of secondary wholesalers; Conference between S.959, Pharmaceutical Quality Security & Accountability Act and H.R. 1919, Safeguarding America's Pharmaceuticals Act of 2013.
Client expense: — · Firm income: $10,000
Matched citations: S.959
Food and Drug Administration Reform Act of 2012
2012 · third_quarter · Firm: HOLLAND & KNIGHT LLP
Educated Members of Congress, Senators and their staff regarding secondary distribution in the drug supply chain. Advocated for accreditation policies to improve quality in the market. Lobbied regarding provisions in drug supply chain legislative proposals prohibiting wholesalers from purchasing drugs from pharmacies. Met with House and Senate Committee staff investigating supply chain security. Congress considered including the provisions in S. 3187, The Food & Drug Administration Safety & Innovation Act and HR 5651, the Food & Drug Administration Reform Act of 2012
Client expense: — · Firm income: $40,000
Matched citations: HR 5651
Source: Senate LDA